Similar Items: Immunogenicity, Tolerability, and Safety of BA.1-Adapted BNT162b2 Vaccine in 18- to 55-Year-Olds Previously Vaccinated with BNT162b2 or Who Were COVID-19 Vaccine-Naive
- Safety and immunogenicity of BNT162b2 in ART-treated PWH
- Safety of BNT162b2 COVID-19 Vaccine in Pregnancy: A Systematic Review
- Interim Effectiveness of 2025–2026 mRNA-1283 and BNT162b2 COVID-19 Vaccines Against COVID-19-Related Outcomes Among Adults Aged ≥ 65 Years in the United States
- Primary immune trajectories following a single BNT162b2 vaccination scheme in SARS-CoV-2–naïve individuals
- Cost-Effectiveness of Routine Infant Meningococcal B Vaccination in the Netherlands
- Prevalence and risk factors of hepatitis B vaccine non-response in hemodialysis patients: a narrative review